The N-protected amino acid (1.0 eq) was dissolved in DMF. Cs2CO3 (1.0 eq) and allyl bromide (1.3 eq) were added and the mixture was stirred at rt overnight. The solvent was removed and the resulting residue was taken up in EtOAc. The solution was extracted with 1 M HCl (3 x 10 mL) and sat. NaHCO3 (3 x 10 mL), washed with brine and dried over MgSO4.
General procedure for peptide coupling:
The respective Boc-protected amine was dissolved in 2 mL of DCM and HCl (4 M solution in dioxane, 2.0 eq) was added. The mixture was stirred for 2 h and the solvent was removed under reduced pressure. A carboxylic acid (1.0 eq), EDC (1.3 eq), HOBt (1.3 eq) and DIPEA (2.5 eq) were added to the flask. The mixture was dissolved in DCM and the stirred at rt overnight. The solution was diluted with EtOAc and extracted with 1 M HCl (3 x 15 mL) and sat. NaHCO3 (3 x 15 mL). The combined organic phases were washed with brine and dried over MgSO4. The crude product was purified by silica gel column chromatography (DCM/MeOH 50:1).
1.3. General procedure for the synthesis of protected diamines:
The respective Boc-protected diamine and NEt3 (2.0 eq) were dissolved in DCM. Alloc-Cl (1.2 eq) was added dropwise under ice cooling. The reaction mixture was stirred at rt overnight. After removal of the solvent, the residue was taken up in EtOAc and extracted with 1 M HCl (3 x 10 mL), sat. NaHCO3 solution (3 x 10 mL) and brine (1 x 10 mL). The organic phase was dried over MgSO4 and the raw product was purified by silica gel chromatography (DCM/MeOH 50:1). 4 2. Synthesis of peptidic precursors 2.1. Synthesis of Peptide S3 Scheme S1. Synthesis of peptide S3.
Boc-Dab(Alloc)-OH (S1):
Boc-Gln-OH (1.72 g, 7.00 mmol, 1.0 eq) and (Diacetoxyiodo)benzene (2.71 g, 7.40 mmol, 1.20 eq) were dissolved in an ice cold mixture of EtOAc/MeCN/H2O (2:2:1). The mixture was stirred at 50 °C overnight and afterwards extracted with EtOAc (3 x 10 mL). K2CO3 (2.42 g, 17.50 mmol, 2.5 eq) was added to the aqueous phase. A solution of Alloc-Cl (1.01 g, 8.40 mmol, 1.2 eq) in Et2O was added to the flask and the biphasic mixture was stirred at rt overnight. The phases were separated and the aqueous phase was washed with EtOAc (3 x 10 mL) and the organic phases were discarded. The pH was adjusted to 1 and the resulting solution was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with brine and dried over MgSO4. The product was obtained as a yellow oil (985 mg, 3.26 mmol, 47%). 
Synthesis of Peptides S8-S9
Scheme S2. Synthesis of peptides S8-S9.
Boc-Orn(Alloc)-OH (S4):
Boc-Orn(Cbz)-OH (3.66 g, 10.00 mmol, 1.0 eq) and ammonium formate (3.15 g, 50.00 mmol, 5.0 eq) were dissolved in MeOH. Palladium on activated charcoal (10% Pd, 851 mg, 0.80 mmol, 8 mol%) was added and the resulting suspension was stirred for 2 h at rt. The mixture was filtered over Celite, the solvent was removed under reduced pressure. The residue was taken up in H2O and K2CO3 (3.46 g, 25.00 mmol, 2.5 eq) was added. A solution of Alloc-Cl (1.45 g, 12.00 mmol, 1.2 eq) in Et2O was added to the flask and the biphasic mixture was stirred at rt overnight. The phases were separated and the aqueous phase was washed with EtOAc (3 x 10 mL) and the organic phases were discarded. The pH was adjusted to 1 and the resulting solution was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with brine and dried over MgSO4. The product was obtained as a colorless oil (2.90 g, 9.16 mmol, 92%). 
Boc-Lys(Alloc)-OH (S5):
Boc-Lys(Cbz)-OH (2.66 g, 7.00 mmol, 1.0 eq) and ammonium formate (2.21 g, 35.00 mmol, 5.0 eq) were dissolved in MeOH. Palladium on activated charcoal (10% Pd, 745 mg, 0.70 mmol, 10 mol%) was added and the resulting suspension was stirred for 2 h at rt. The mixture was filtered over Celite and the solvent was removed under reduced pressure. The residue was taken up in H2O and K2CO3 (2.42 g, 17.50 mmol, 2.5 eq) was added. A solution of Alloc-Cl (1.01 g, 8.40 mmol, 1.2 eq) in Et2O was added to the flask and the biphasic mixture was stirred at rt overnight. The phases were separated, the aqueous phase was washed with EtOAc (3 x 10 mL) and the organic phases were discarded. The pH was adjusted to 1 and the resulting solution was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with brine and dried over MgSO4. The product was obtained as a colorless oil (1.36 g, 4.11 mmol, 59% 
Synthesis of Peptide S11
Scheme S3. Synthesis of peptide S11.
Boc-Leu-Gly-NH2 (S10): Synthesized after general procedure 1.2. Boc-Leu-OH (2.31 g, 10.00 mmol, 1.0 eq), glycinamide hydrochloride (1.11 g, 10.00 mmol, 1.0 eq), EDC (2.49 g, 13.00 mmol, 1.3 eq), HOBt (1.76 g, 13.00 mmol, 1.3 eq) and DIPEA (3.23 g, 25.00 mmol, 2.5 eq) were dissolved in DCM and the mixture was stirred at rt overnight. The solution was diluted with EtOAc and extracted with 1 M HCl (3x15 mL) and sat.
NaHCO3 (3x15 mL). The combined organic phases were washed with brine and dried over MgSO4. The crude product was purified by silica gel column chromatography (DCM/MeOH 50:1). The product was obtained as a colorless foam (2.00 g, 6.94 mmol, 69% 
tert-butyl (S)-(1-(((((allyloxy)carbonyl)amino)methyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (S11):
Boc-Leu-Gly-NH2 (S13, 287 mg, 1.00 mmol, 1.0 eq) and (Diacetoxyiodo)benzene (419 mg, 1.30 mmol, 1.3 eq) were dissolved in a mixture of MeCN (5 mL) and allyl alcohol (5 mL) and heated to 50 °C overnight. 
Synthesis of Peptides S15-S17
Scheme S4. Synthesis of peptides S15-S17. 
tert-butyl (S)-(1-((2-(((allyloxy)carbonyl)amino)ethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (S15):
Synthesized after general procedure 1.2. S12 (489 mg, 2.00 mmol), HCl (4 M solution in Dioxane, 1 mL, 
tert-butyl (S)-(1-((2-(((allyloxy)carbonyl)amino)propyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (S16):

tert-butyl (S)-(1-((2-(((allyloxy)carbonyl)amino)butyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (S17):
Synthesized after general procedure 1.2. S14 (272 mg, 1.00 mmol), HCl (4 M solution in Dioxane, 1 mL, 
Synthesis of Peptide S19
Scheme S5. Synthesis of peptide S19.
Piperazine S18: Boc-Piperazine (1.12 g, 6.00 mmol, 1.0 eq) and NEt3 (729 mg, 7.20 mmol, 1.2 eq) were dissolved in DCM. The solution was cooled to 0 °C and Alloc-Cl (868 mg, 7.20 mmol, 1.2 eq) was added dropwise. The mixture was allowed to warm to rt overnight and was washed with 1 M HCl (3 x 10 mL), brine and dried over anhydrous MgSO4. The product was obtained as a yellow oil (1.38 g, 5.10 mmol, 85%). 
Synthesis of Peptides S21-S26
11 Scheme S6. Synthesis of peptides S21-S26.
Boc-Leu-OAll (S20): Synthesized after general procedure 1.1. Boc-Leu-OH (5.00 g, 21.62 mmol, 1.0 eq) and Cs2CO3 (7.04 g, 21.62 mmol, 1.0 eq) were dissolved in DMF. Allyl bromide (3.39 g, 28.11 mmol, 1.3 eq) was added and the solution was stirred for 5 h at rt. The solvent was removed under reduced pressure and the residual slurry taken up in EtOAc. The organic phase was washed with sat. NaHCO3 solution (3 x 15 mL) and brine and dried over MgSO4. The solvent was removed to give the product as a yellow oil (5.12 g, 18.85 mmol, 87%). Were n is the number of protons, I is the integral, M is the molecular weight, m is the mass and P is the purity (in %). Indices IC and a denominate internal calibrant or analyte respectively. For the determination of analyte integral, the sum of suitable, non-overlapping signals was used. The OCH3 signal of DMT was not considered for quantitative analysis, since transesterification with deuterated methanol can result in artificial signal reduction. 
